Eupraxia Phase 2b RESOLVE Trial Update: A Promising Step Forward for EoE Treatment

Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Stock Price: US$5.40 | Market Cap: ~US$194M Recommendation: Buy | Target Price: US$12.00 On July 8, 2025, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) announced a significant milestone in its clinical development program, dosing the first patient in the placebo-controlled Phase 2b portion of the RESOLVE trial for […]

Eupraxia’s EoE Breakthrough: Cohort 6 Shines Bright, Cohort 5 Holds Strong With 24-Week Follow-up

Eupraxia Pharmaceuticals Inc. (EPRX – Nasdaq and TSX) is a clinical-stage biotechnology company headquartered in Victoria, British Columbia, Canada. The company focuses on developing locally delivered, extended-release alternatives to currently approved drugs. Their goal is to provide targeted, long-lasting activity with fewer side effects. Eupraxia’s lead product candidate, EP-104GI for treating eosinophilic esophagitis (EoE). EoE is a […]

Eupraxia – The Precision Delivery Platform

Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company headquartered in Victoria, British Columbia, Canada. The company focuses on developing locally delivered, extended-release alternatives to currently approved drugs. Their goal is to provide targeted, long-lasting activity with fewer side effects. Eupraxia’s lead product candidate, EP-104GI for treating eosinophilic esophagitis (EoE). EoE is a chronic, immune-mediated […]